header_edited.jpg

AUROCIS

GOLD NANOPARTICLES FUNCTIONALIZED WITH Pt-BASED DRUGS TO ENHANCE EFFICACY OF CHEMOTHERAPY AND RADIOTHERAPY TREATMENTS

 

AUROCIS

Conjugating platinum based chemotherapy drugs with gold nanoparticles using pH-sensitive linkers to target intravenous delivery of chemotherapy drugs and locally enhance radiotherapy and imaging, increasing efficacy and reducing toxicity of cancer treatment

 

HIGH QUALITY NANOPARTICLES

AUROCIS developed methods that yield high quality gold nanoparticles:

  • Size control & narrow size distribution.

  • Optimization of scale-up with our industrial partner.

  • Functionalization with a variety of pH-sensitive linkers.

  • Maximize the loading of Pt-based drugs to reach therapeutic doses.

209-200000X-0002_edited_edited.jpg
 

CHEMOTERAPY ENHANCEMENT

  • Aurocis efficacy in in vitro and in vivo models. Aurocis demonstrated its potential against a variety of tumor models including lung, ovarian, testicular, bladder, and colorectal.​

  • No toxicity observed in mouse models. No organs affected by treatment. No nephrotoxicity, which is dose limiting in classic Pt-based chemotherapies.

  • Ongoing experiments with orthotopic implants in mice of patient-derived tumor cells (pdx) to further explore potential therapies

 

RADIOTHERAPY ENHANCEMENT

  • Gold nanoparticles metallic nature (Z=79) has been proved to be an excellent radiosensitizer.

  • Increase effective dose in the vicinity of the nanoparticle.

  • Lower toxicity to surrounding tissues.

  • Synergy between chemotherapy and radiotherapy promoted by Aurocis: Radiotherapy improves Aurocis delivery and penetration, chemotherapy enhances DNA damage by X-rays.

cells.png
 

CONTACT

10 Rue Antoine Jans L-1820 Luxembourg (Lëtzebuerg)

 

©2019 by Aurocis